🇺🇸 FDA
Pipeline program

Dexlansoprazole

TAK-390MR(OD)_107

Approved small_molecule completed

Quick answer

Dexlansoprazole for Gastroesophageal Reflux Disease is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 4 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Gastroesophageal Reflux Disease
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials